Relationship between factor VIII replacement therapy and joint damage in severe haemophilia.
Most of the physical, psychosocial and financial disability in severe haemophilia A is caused by the effects of recurrent haemarthroses and of chronic arthritis. Recent evidence suggests that this morbidity is related to insufficient factor VIII replacement therapy, not only quantitative (annual dose) but also qualitative (need for regular long-term prophylaxis). The recent development of recombinant factor VIII may increase the acceptability of prophylaxis to parents and patients, and hence reduce morbid outcomes.
Lowe
G D
GD
Vascular Medicine, University of Glasgow, West of Scotland Haemophilia Comprehensive Care Centre, Royal Infirmary, UK.
D001168:Arthritis / Q000209:etiology / Q000517:prevention & control; D005169:Factor VIII / Q000008:administration & dosage* / Q000627:therapeutic use; D006395:Hemarthrosis / Q000209:etiology / Q000517:prevention & control; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007592:Joint Diseases / Q000209:etiology* / Q000517:prevention & control; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D011994:Recombinant Proteins; D005169:Factor VIII